Here we have outlined the recent (2011–2022) developments in the synthesis of modified indomethacin-based analogues for the selective inhibition of COX-2 and then highlighted the synthesis of indoles as inhibitors of other inflammatory mediators such as nitric oxide (NO) radicals, lipoxygenase (LOX) enzymes, reactive oxygen species (ROS) and interleukin (IL).